Earnings Call Summary | CareDx(CDNA.US) Q1 2024 Earnings Conference
Earnings Call Summary | CareDx(CDNA.US) Q1 2024 Earnings Conference
The following is a summary of the CareDx, Inc. (CDNA) Q1 2024 Earnings Call Transcript:
以下是CareDx, Inc.（CDNA）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
CareDx reported Q1 revenue of $72 million, up 10% from the prior quarter.
The revenue from Testing Services increased 8% quarter-over-quarter to $53.8 million.
The company's products business achieved 25% year-over-year growth, resulting in $8.6 million in revenue.
The company raised its revenue guidance for 2024 to $274-282 million.
The company expects a gross margin at the high end of their reported range of around 63% to 65%.
CaredX公佈的第一季度收入爲7200萬美元，比上一季度增長10％。
測試服務的收入同比增長8％，達到5,380萬美元。
該公司的產品業務實現了25％的同比增長，收入爲860萬美元。
該公司將2024年的收入預期提高至2.74億至2.82億美元。
該公司預計，毛利率將達到其報告區間的最高水平，約爲63％至65％。
Business Progress:
業務進展：
CareDx continues to gain momentum in Testing Services, with an increase in test volumes.
The company is experiencing growth in their Patient and Digital Solutions and product businesses.
The company's initiatives to expand organ transplant surveillance services, particularly in Heart, Kidney, and Lung.
CareDx's acquisition of MediGO, a digital transplant management solution, is expected to boost future business prospects and revenue.
Adjusted EBITDA losses for the full year 2024 are predicted to improve to $14 million to $24 million.
隨着測試量的增加，CareDx 在測試服務領域繼續保持勢頭。
該公司的患者和數字解決方案及產品業務正在增長。
該公司擴大器官移植監測服務的舉措，特別是在心臟、腎臟和肺部。
CaredX對數字移植管理解決方案MediGo的收購有望提振未來的業務前景和收入。
預計2024年全年調整後的息稅折舊攤銷前利潤虧損將增至1,400萬美元至2400萬美元。
More details: CareDx IR
更多詳情： CaredX IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。